Doctor profile · Federal record
Dr. ABHAYA TRIVEDI
Pulmonary Disease Physician (CMS: PULMONARY DISEASE) · Critical Care Medicine (Internal Medicine) Physician · CHICAGO, IL
- NPI 1619293800
- Accepts Medicare
- 16 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
1740 W TAYLOR ST
CHICAGO, IL 606127232
(866) 600-2273 - Mailing address
-
420 E OHIO ST, APT 8D
CHICAGO, IL 606113390
Credentials & registration
- NPI registered
- April 2010 — 16 yrs on file
- Profile last updated
- September 21, 2017
- Year of graduation
- 2010 — 16 yrs since
- Specialty taxonomy
- 207RP1001X — NUCC code
- State license (1)
- Illinois #036.143182
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1619293800. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
964
Distinct HCPCS
10
Medicare allowed
$80,405
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
94729 |
Test to examine how well the lungs exchange gases | 133 | 131 | $9 | |
94726 |
Test to determine lung volumes using sensors | 132 | 130 | $12 | |
94375 |
Test to measure rate of airflow | 127 | 125 | $15 | |
99291 |
Critical care, first 30-74 minutes | 106 | 58 | $231 | |
99233 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 95 | 44 | $127 | |
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 79 | 51 | $151 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 69 | 46 | $104 | |
94060 |
Test to measure expiratory airflow and volume changes before and after medication administration | 54 | 54 | $10 | |
99232 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 45 | 26 | $85 | |
99223 |
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 26 | 24 | $185 |
In context: peer comparison
Among 66 peers in this city , average services per provider: 90. This provider delivers 11× the peer median.Open Payments
Industry payments received
All-time total
$230
Transactions
3
Manufacturers
2
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $135.42 | |
| GENZYME CORPORATION | 1 | $94.42 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
938
Patients
206
Total drug cost
$1,121,605
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) | Brand | 287 | 55 | $215,421 |
| Albuterol Sulfate Hfa (Albuterol Sulfate) | Brand | 138 | 45 | $5,978 |
| Symbicort (Budesonide/Formoterol Fumarate) | Brand | 77 | 22 | $36,118 |
| Tezspire (Tezepelumab-Ekko) | Brand | 72 | 0 | $323,518 |
| Ventolin Hfa (Albuterol Sulfate) | Brand | 53 | 18 | $3,410 |
| Prednisone | Generic | 50 | 31 | $190 |
| Breo Ellipta (Fluticasone/Vilanterol) | Brand | 41 | 0 | $19,536 |
| Fluticasone Propionate | Generic | 41 | 22 | $690 |
| Fasenra Pen (Benralizumab) | Brand | 38 | 0 | $234,382 |
| Nucala (Mepolizumab) | Brand | 31 | 0 | $247,845 |